BAKER BROS. ADVISORS LP - 04 Nov 2026 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: KOD
Reported as of: 04 Nov 2026
Net transaction value: +$24,340,836
SEC form: 4
Accepted by SEC: 06 Nov 2026, 16:55:41 UTC
Prior SEC filing: 02 Oct 2026
Source filing: View source filing
Reporting owner signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing

Filing notes and source

Key filing fact

BAKER BROS. ADVISORS LP filed Form 4 for Kodiak Sciences Inc. (KOD) on 06 Nov 2026.

Key facts

This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for Kodiak Sciences Inc. (KOD).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Nov 2026, 16:55.

Change

Previous filing in this sequence was filed on 02 Oct 2026.
Current net transaction value: +$24,340,836.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0001263508 Primary reporting owner

BAKER BROS. ADVISORS LP

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 06 Nov 2026

CIK 0001551139

667, L.P.

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 06 Nov 2026

CIK 0001580575

Baker Bros. Advisors (GP) LLC

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 06 Nov 2026

CIK 0001363364

Baker Brothers Life Sciences LP

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President
Signature date: 06 Nov 2026

CIK 0001087940

BAKER FELIX

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Felix J. Baker
Signature date: 06 Nov 2026

CIK 0001087939

BAKER JULIAN

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Julian C. Baker
Signature date: 06 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KOD transaction

Common Stock

Purchase

Transaction value: $861,174
Shares: +8,742
Change %: +0.52%
Price: $98.51
Shares after: 1,678,469
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $861,174
Shares: +8,742
Change %: +0.52%
Price: $98.51
Shares after: 1,678,469
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $861,174
Shares: +8,742
Change %: +0.52%
Price: $98.51
Shares after: 1,678,469
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $861,174
Shares: +8,742
Change %: +0.52%
Price: $98.51
Shares after: 1,678,469
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $861,174
Shares: +8,742
Change %: +0.52%
Price: $98.51
Shares after: 1,678,469
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $861,174
Shares: +8,742
Change %: +0.52%
Price: $98.51
Shares after: 1,678,469
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $14,965,245
Shares: +151,916
Change %: +0.75%
Price: $98.51
Shares after: 20,343,130
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $14,965,245
Shares: +151,916
Change %: +0.75%
Price: $98.51
Shares after: 20,343,130
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $14,965,245
Shares: +151,916
Change %: +0.75%
Price: $98.51
Shares after: 20,343,130
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $14,965,245
Shares: +151,916
Change %: +0.75%
Price: $98.51
Shares after: 20,343,130
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $14,965,245
Shares: +151,916
Change %: +0.75%
Price: $98.51
Shares after: 20,343,130
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $14,965,245
Shares: +151,916
Change %: +0.75%
Price: $98.51
Shares after: 20,343,130
Date: 04 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $463,293
Shares: +4,703
Change %: +0.28%
Price: $98.51
Shares after: 1,683,172
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $463,293
Shares: +4,703
Change %: +0.28%
Price: $98.51
Shares after: 1,683,172
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $463,293
Shares: +4,703
Change %: +0.28%
Price: $98.51
Shares after: 1,683,172
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $463,293
Shares: +4,703
Change %: +0.28%
Price: $98.51
Shares after: 1,683,172
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $463,293
Shares: +4,703
Change %: +0.28%
Price: $98.51
Shares after: 1,683,172
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $463,293
Shares: +4,703
Change %: +0.28%
Price: $98.51
Shares after: 1,683,172
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F1, F2, F3

KOD transaction

Common Stock

Purchase

Transaction value: $8,051,124
Shares: +81,729
Change %: +0.4%
Price: $98.51
Shares after: 20,424,859
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $8,051,124
Shares: +81,729
Change %: +0.4%
Price: $98.51
Shares after: 20,424,859
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $8,051,124
Shares: +81,729
Change %: +0.4%
Price: $98.51
Shares after: 20,424,859
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $8,051,124
Shares: +81,729
Change %: +0.4%
Price: $98.51
Shares after: 20,424,859
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $8,051,124
Shares: +81,729
Change %: +0.4%
Price: $98.51
Shares after: 20,424,859
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

KOD transaction

Common Stock

Purchase

Transaction value: $8,051,124
Shares: +81,729
Change %: +0.4%
Price: $98.51
Shares after: 20,424,859
Date: 05 Nov 2026
Ownership: See Footnotes
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Footnote F2

Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.

Footnote F3

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Footnote F4

After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC remarks

Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Kodiak Sciences Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer.